Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, Théroux P, Marquis JF, Chan YK, Venkatesh G, Jessel A. Flather MD, et al. Among authors: sussex b. Eur Heart J. 2000 Sep;21(17):1473-81. doi: 10.1053/euhj.1999.2005. Eur Heart J. 2000. PMID: 10952840 Clinical Trial.
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators. Mathew J, et al. Among authors: sussex b. Circulation. 2001 Oct 2;104(14):1615-21. doi: 10.1161/hc3901.096700. Circulation. 2001. PMID: 11581138 Clinical Trial.
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Warfarin Antiplatelet Vascular Evaluation Trial Investigators; Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, Sussex B, Liu L, Guzman R, Cina C, Crowell R, Keltai M, Gosselin G. Warfarin Antiplatelet Vascular Evaluation Trial Investigators, et al. Among authors: sussex b. N Engl J Med. 2007 Jul 19;357(3):217-27. doi: 10.1056/NEJMoa065959. N Engl J Med. 2007. PMID: 17634457 Free article. Clinical Trial.
Canadian-led capacity-building in biostatistics and methodology in cardiovascular and diabetes trials: the CANNeCTIN Biostatistics and Methodological Innovation Working Group.
Thabane L, Wells G, Cook R, Platt R, Pogue J, Pullenayegum E, Matthews D, McCready T, Devereaux PJ, Cairns JA, Yusuf S; CANadian Network and Centre for Trials Internationally (CANNeCTIN) Investigators. Thabane L, et al. Trials. 2011 Feb 18;12:48. doi: 10.1186/1745-6215-12-48. Trials. 2011. PMID: 21332987 Free PMC article.
Myocardial infarction patients in the 1990s--their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study.
Rouleau JL, Talajic M, Sussex B, Potvin L, Warnica W, Davies RF, Gardner M, Stewart D, Plante S, Dupuis R, Lauzon C, Ferguson J, Mikes E, Balnozan V, Savard P. Rouleau JL, et al. Among authors: sussex b. J Am Coll Cardiol. 1996 Apr;27(5):1119-27. doi: 10.1016/0735-1097(95)00599-4. J Am Coll Cardiol. 1996. PMID: 8609330 Free article.
The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure.
Liu P, Arnold M, Belenkie I, Howlett J, Huckell V, Ignazewski A, LeBlanc MH, McKelvie R, Niznick J, Parker JD, Rao V, Ross H, Roy D, Smith S, Sussex B, Teo K, Tsuyuki R, White M, Beanlands D, Bernstein V, Davies R, Issac D, Johnstone D, Lee H, Moe G, Newton G, Pflugfelder P, Roth S, Rouleau J, Yusuf S; Canadian Cardiovascular Society. Liu P, et al. Among authors: sussex b. Can J Cardiol. 2001 Dec;17 Suppl E:5E-25E. Can J Cardiol. 2001. PMID: 11773943 Review. English, French. No abstract available.
The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure.
Liu P, Arnold JM, Belenkie I, Demers C, Dorian P, Gianetti N, Haddad H, Howlett J, Ignazewski A, Jong P, McKelvie R, Moe G, Parker JD, Rao V, Rouleau JL, Teo K, Tsuyuki R, White M, Huckel V, Issac D, Johnstone D, LeBlanc MH, Lee H, Newton G, Niznick J, Ross H, Roth S, Roy D, Smith S, Sussex B, Yusuf S; Canadian Cardiovascular Society. Liu P, et al. Among authors: sussex b. Can J Cardiol. 2003 Mar 31;19(4):347-56. Can J Cardiol. 2003. PMID: 12704478 Review. No abstract available.
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).
McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators. McMurray JJ, et al. Eur J Heart Fail. 2013 Mar;15(3):334-41. doi: 10.1093/eurjhf/hfs204. Epub 2013 Jan 17. Eur J Heart Fail. 2013. PMID: 23329651 Free PMC article. Clinical Trial.
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.
Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, Kastelein JJ, Keyserling C, Klepp H, Koenig W, L'Allier PL, Lespérance J, Lüscher TF, Paolini JF, Tawakol A, Waters DD; Can HDL Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators. Tardif JC, et al. Eur Heart J. 2014 Dec 7;35(46):3277-86. doi: 10.1093/eurheartj/ehu171. Epub 2014 Apr 29. Eur Heart J. 2014. PMID: 24780501 Free PMC article. Clinical Trial.
88 results